Depression treatment often incorporates anti-depressant medicine and psychotherapy. Psychotherapy alone, involving cognitive and behavioral awareness and change as well as interpersonal training, education, and family therapy, may effectively treat mild cases of mental depression. Untreated depression can worsen and become more resistant to treatment. The newest class of anti-depressant medications increase the availability in the brain of serotonin, dopamine, and norepinephrine and include venlafaxine (trade name Effexor), nefazodone (trade name Serzone), bupropion (trade name Wellbutrin), mirtazapine (trade name Remeron), and trazodone (trade name Desyrel). Anti-depressant medications classified as selective serotonin reuptake inhibitors (SSRIs) include escitalopram (trade name Lexapro), citalopram (trade name Celexa), fluoxetine (trade name Prozac), paroxetine (trade name Paxil), and sertraline (trade name Zoloft). These anti depression drugs allow the neurotransmitter serotoni...
Earlier this month, the Food and Drug Administration (FDA) approved Lexapro (escitalopram oxalate) for the acute and maintenance treatment of major depressive disorder (MDD) in adolescents 12- to 17-years-old.
Here's some basic information about the approval from a Forest Laboratories press release (I have put some parts in bold for added attention):
"The approval of Lexapro for the treatment of adolescent depression was supported by two placebo-controlled studies, one conducted in adolescent patients taking Lexapro and one conducted in children and adolescents taking citalopram (Celexa) . In an 8-week flexible- dose, placebo-controlled study that compared Lexapro 10-20 mg/day to placebo in 12 to 17 year old patients reported in 2008, Lexapro showed statistically significant greater mean improvement from baseline, compared to placebo, on the Children's Depression Rating Scale-Revised (CDRS-R).
In another 8-week, flexible-dose, placebo-controlled study, children and adol...
Christos Ballas, MD, is an academic and forensic psychiatrist.
He graduated from Jefferson Medical College and completed his
residency at the Hospital of the University of Pennsylvania. He
joined the faculty of the University of Pennsylvania School of
Medicine as an Assistant Professor. He works as inpatient and
consult/liaison psychiatrist, in addition to maintaining a private
practice dedicated to forensics.
Dr. Ballas has published and lectured extensively. His medical
interests include forensic issues and violence, pharmacology, and
healthcare policy. Dr. Ballas is also a talented artist and a
technology enthusiast. One of his current projects include a novel
about the end of the internet.
Dr. Ballas looks forward to answering your questions about
depression. You can send your questions to
You should knowAnswers to your question are meant to provide general health information but should not replace medical advice you receive from a doctor. No answers should be viewed as a diagnosis or recommended treatment for a condition. Content posted by community members does not necessarily reflect the views of Remedy Health Media, which also reserves the right to remove material deemed inappropriate.